Oasmia Pharmaceutical AB (STO:OASM) announced on Monday that it has appointed Peter Selin as chief business officer, reporting directly to Dr Francois R. Martelet, CEO.

Selin, who has almost 20 years of business development experience, most recently serving as VP Pharma Business Operations at Inceptua Group, a pharmaceuticals company and services provider. His prior roles include appointments at Sobi, where he served as VP Corporate Development and managed partnering and licensing activities and corporate strategy projects, as well as manager, Strategy & Transformation at Ernst & Young.

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology.